The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical features and response to immune checkpoint inhibitors (ICIs) in pregnancy-associated melanoma (PAM).
 
Daniel Ying Wang
No Relationships to Disclose
 
Carina N. Owen
Travel, Accommodations, Expenses - MSD
 
David James Palmieri
No Relationships to Disclose
 
Justine Vanessa Cohen
Consulting or Advisory Role - Genzyme
 
Zeynep Eroglu
Consulting or Advisory Role - Array BioPharma; Compugen; Regeneron
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Tesaro
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)
 
Ryan J. Sullivan
Honoraria - Roche/Genentech
Consulting or Advisory Role - ACI Clinical; Amgen; Array BioPharma; Biodesix; BiolineRx; Compugen; Merck; Novartis; Replimune; Syndax; Takeda; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)
Other Relationship - Boehringer Ingelheim
 
Justin M. Balko
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Incyte
Patents, Royalties, Other Intellectual Property - FCRL6 as an immunotherapy target; Patent on use of HLA-DR/MHC expression to predict response to immunotherapies
Other Relationship - NanoString Technologies
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
Travel, Accommodations, Expenses - Genentech